Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

NCT01420783 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematopoietic Neoplasm

Interventions

DRUG: SAR302503

Sponsor

Bristol-Myers Squibb